"{\n \"business_address\": \"358 S MAIN ST, BURLINGTON, NC 27215\", \n \"business_phone_no\": \"3362291127\", \n \"ceo\": \"David P. King\", \n \"cik\": \"0000920148\", \n \"company_url\": \"www.labcorp.com\", \n \"employees\": 52000, \n \"entity_legal_form\": \"CORPORATION\", \n \"entity_status\": \"ACTIVE\", \n \"hq_address1\": \"C/O Treasury\", \n \"hq_address2\": \"531 South Spring Street\", \n \"hq_address_city\": \"Burlington\", \n \"hq_address_postal_code\": \"27215\", \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"North Carolina\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"Delaware\", \n \"industry_category\": \"Health Services\", \n \"industry_group\": \"Medical Laboratories & Research\", \n \"latest_filing_date\": \"2017-08-02\", \n \"legal_name\": \"LABORATORY CORP OF AMERICA HOLDINGS\", \n \"lei\": \"OZ7UA8IXAIFILY2VZH07\", \n \"long_description\": \"Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. The company offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, tests for sexually-transmitted diseases, HCV tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. It also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, the company provides drug development solutions, as well as laboratory testing services. Further, it provides its testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Duke University, Johns Hopkins University, Boston University, Columbia University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.\", \n \"mailing_address\": \"358 S MAIN ST, BURLINGTON, NC 27215\", \n \"name\": \"Laboratory Corporation of America Holdings\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000D9DMK0\", \n   \"composite_figi_ticker\": \"LH:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": \"BBG000D9DMK0\", \n   \"figi_exch_cntry\": \"US\", \n   \"figi_ticker\": \"LH:US\", \n   \"figi_uniqueid\": \"EQ0010104000001000\", \n   \"last_crsp_adj_date\": \"2002-05-13\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"LABORATORY CRP OF AMER HLDGS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S7RX54\", \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"LH\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GH3153\", \n   \"composite_figi_ticker\": \"LAB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000GH48C9\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"LAB:GM\", \n   \"figi_uniqueid\": \"EQ0010104000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"LABORATORY CORP. OF AMERICA HOLDINGS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S7RX54\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"LAB\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GH3153\", \n   \"composite_figi_ticker\": \"LAB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000GH49B8\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"LAB:GB\", \n   \"figi_uniqueid\": \"EQ0010104000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"LABORATORY CORP. OF AMERICA HOLDINGS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S7RX54\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"LAB\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GH3153\", \n   \"composite_figi_ticker\": \"LAB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000GH43Z5\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"LAB:GD\", \n   \"figi_uniqueid\": \"EQ0010104000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"LABORATORY CORP. OF AMERICA HOLDINGS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S7RX54\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"LAB\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GH3153\", \n   \"composite_figi_ticker\": \"LAB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000GH43M9\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"LAB:GF\", \n   \"figi_uniqueid\": \"EQ0010104000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"LABORATORY CORP. OF AMERICA HOLDINGS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S7RX54\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"LAB\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GH3153\", \n   \"composite_figi_ticker\": \"LAB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000GH3153\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"LAB:GR\", \n   \"figi_uniqueid\": \"EQ0010104000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"LABORATORY CORP. OF AMERICA HOLDINGS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S7RX54\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"LAB\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GH3153\", \n   \"composite_figi_ticker\": \"LAB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000GH47G7\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"LAB:GS\", \n   \"figi_uniqueid\": \"EQ0010104000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"LABORATORY CORP. OF AMERICA HOLDINGS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S7RX54\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"LAB\"\n  }\n ], \n \"short_description\": \"Laboratory Corp. of America Holdings operates as an independent clinical laboratory company. It operates through the following segments: LabCorp Diagnostics and Covance Drug Development. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment provides drug development solutions on a worldwide basis, primarily to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.\", \n \"sic\": 8071, \n \"standardized_active\": true, \n \"stock_exchange\": \"NYSE\", \n \"template\": \"industrial\", \n \"ticker\": \"LH\"\n}"